• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Jason J. Luke, MD


  • Luke JJ, Schwartz GK.Chemotherapy in the management of advanced cutaneous malignant melanoma.Clin Dermatol.;31(3):290-7.
  • Luke JJ, Rubinstein LV, Smith GL, Ivy SP, Harris PJ.Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.Melanoma Res. 2013 Apr;23(2):152-8.
  • Luke J, Mirkin J, Bach P.Improving quality and addressing the rising costs of cancer care: two birds, one stone.J Oncol Pract. 2011 Nov;7(6):402-4.
  • Luke JJ, D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Maki RG, de Stanchina E, Musi E, Singer S, Schwartz GK.The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and phase I clinical trial.Clin Cancer Res. 2012 Feb 28.
  • Luke JJ, Hodi FS.Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma.Clin Cancer Res. 2012 Jan 1;18(1):9-14.
  • Bach PB, Mirkin JN, Luke JJ.Episode-based payment for cancer care: a proposed pilot for Medicare.Health Aff (Millwood). 2011 Mar;30(3):500-9.
  • Luke JJ, Van De Wetering CI, Knudson CM.Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability.Cell Death Differ. 2003 Jun;10(6):740-8.